Fig 3. The effect of p53 dosage on Kras-driven hematolymphopoietic tumorigenesis.

Percent of Rosa26^CreERT2/+ mice of the indicated genotypes (n = 5–8) with the indicated type of hematolymphopoietic lesions of myeloproliferative disease and lymphomas. Pairwise comparisons of hematolymphopoietic tumor incidence in each genotype with versus without Super p53 were performed using Chi-square test. ****: p-value <0.0001. Data values of hematolymphopoietic tumor incidence and presence of hematolymphopoietic infiltrates in different tissues are provided in S4 Appendix.